MOTS-c: what the research actually shows
The distinction between “your body’s MOTS-c goes up when you exercise” and “injected MOTS-c does anything in people” is the whole story. The second has not been tested.
Why I looked into this
MOTS-c gets discussed in two completely different registers. In the basic-science literature, it is an interesting endogenous peptide that appears to play a role in metabolic signaling between the mitochondria and the nucleus. In the biohacking register, it is marketed as an injectable to improve metabolism, fat loss, and longevity.
Those are two different claims. One is supported in humans. The other has never been tested in humans. That distinction is the whole monograph.
What MOTS-c actually is
MOTS-c stands for mitochondrial open reading frame of the twelve S rRNA type-c. It is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, first characterized in 2015. It appears to function as a signaling molecule, translocating from the mitochondrion to the nucleus under metabolic stress to regulate gene expression.
Mechanistically, in cell and rodent models it has been associated with AMPK activation, improved glucose uptake, and enhanced insulin sensitivity. The human evidence on these mechanisms is inferential, not direct.
What the human research shows
Do published trials of exogenous MOTS-c exist?
No. A PubMed and ClinicalTrials.gov search in April 2026 returns zero published human trials in which MOTS-c was administered to subjects as a drug at any dose, for any indication, by any route.
What human data does exist?
Published human work on MOTS-c in the peer-reviewed record measures the body’s own circulating levels:
- Dieli-Conwright et al. 2021, Scientific Reports. Secondary analysis of a 16-week exercise RCT in breast cancer survivors, measuring endogenous plasma MOTS-c. Exercise increased MOTS-c.
- von Walden et al. 2021, Journal of Applied Physiology. Randomized crossover of acute endurance exercise, measuring endogenous circulating MOTS-c increase post-exercise.
- Cuyas et al. 2022, Aging. Sub-analysis of the METTEN RCT in HER2+ breast cancer measuring how neoadjuvant chemotherapy plus metformin modulated endogenous MOTS-c.
- Elhusseiny et al. 2025, MSSE. Repeated heat stress RCT measuring endogenous MOTS-c and FGF21.
Every one of these measured what the human body does with its own MOTS-c, not what injecting it does.
What the research does not show in humans
- Zero trials of injected MOTS-c at any dose
- No human evidence for fat loss as a drug effect
- No human evidence for osteoporosis
- No human evidence for exercise capacity as a drug effect
- No human evidence for longevity endpoints
- No human safety data on exogenous MOTS-c, any route, any duration
Known safety signals in humans
There are no human safety data on exogenous MOTS-c because there have been no human administration studies. Community reports are anecdotal and have no controlled basis.
That absence is itself a safety signal. Immunogenicity, pharmacokinetics, dose-response, and long-term effects are all open questions for any peptide that has never been through Phase 1 in humans.
FDA and legal status in the US
The July 23 PCAC meeting will review MOTS-c for obesity and osteoporosis as a proposed 503A addition. A vote in either direction is possible. Any final change requires separate rulemaking after the vote.
How to evaluate a source: the safety framework
I do not name vendors. I do not link to sellers. The goal is harm reduction, not facilitation.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable address
- Transparent about mass-spec identity verification
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No identity verification on the peptide itself
- Sells Category 2 substances for human use
The wrinkle for MOTS-c specifically
Because there is no human pharmacology data at all, the risk of taking what a source says on faith is higher than for peptides with at least Phase 1 data. Identity and purity matter more, not less.
Cost reality
Compounding a peptide that has never had human pharmacology studies means the compounder is reconstituting a research-grade material. A legitimate operation will say so plainly.
Questions worth asking any source
Is the pharmacy 503A-licensed? Can they provide a COA from a third-party lab? What identity verification do they perform? Where is the physical facility? If a source dodges, that is the answer.
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective. Your situation is not my situation.
The honest version is that MOTS-c is the peptide I find most scientifically interesting and least ready for use. The basic biology, how a peptide encoded inside the mitochondrial genome signals back to the nucleus, is a genuinely new idea worth reading about.
Selling MOTS-c online for weight loss today is selling a hypothesis. The hypothesis might turn out to be correct. It also might not. Nobody has run the study that would tell you.
I have not used MOTS-c and I am not planning to. The combination of zero human trials, no pharmacology, and no identity verification in the gray market is a bet I would not take.
Until that exists, MOTS-c belongs in the “I am watching this one closely, from the sidelines” bucket. The July advisory vote does not change that. The evidence base does.
Questions to ask your doctor
If you are considering MOTS-c or want to have an honest conversation about it, these are the questions I would bring.
- Given that no published human trials of exogenous MOTS-c exist, what is your view on the risk of trying it for my situation?
- Are there FDA-approved options for the goal I am after (weight loss, bone health, metabolic health)?
- What lifestyle interventions would you want me to exhaust first before considering a research peptide?
- What would you monitor if I decided to proceed anyway, and how often?
- Are there medications I am taking that would concern you as an interaction?
- What would change your view on MOTS-c, and what data would you want to see?
What to do next
Read the FDA review article
The July 2026 PCAC meeting is the context everyone will be reading MOTS-c through for the next three months.
Open the FDA article →Download the visit-prep packet
Walk into your next appointment with the evidence summary and six questions ready.
Get the packet →Work through the 503A checklist
Evergreen source-safety checklist. Use it for any peptide source.
Open the checklist →Sources
- Dieli-Conwright et al. 2021, Sci Rep 11:16916. Exercise RCT secondary analysis, endogenous MOTS-c.
- von Walden et al. 2021, J Appl Physiol 131(3):1035-1042. Endurance exercise crossover, endogenous MOTS-c.
- Cuyas et al. 2022, Aging 15(4):892-897. METTEN sub-analysis, endogenous MOTS-c and metformin.
- Elhusseiny et al. 2025, Med Sci Sports Exerc 57(12):2764-2774. Heat stress RCT, endogenous MOTS-c biomarker.
- FDA, Category 2 interim list of bulk drug substances.
- Federal Register, April 16, 2026. PCAC meeting notice, docket FDA-2025-N-6895.
Every cited study measured the body’s own MOTS-c in response to exercise, training, or pharmacology. None administered exogenous MOTS-c.
Related monographs
BPC-157
Same review cycle, same evidence gap, different marketed use case.
TB-500
Small Phase 2 data on full TB-4 for dry eye and ulcers. No muscle-injury evidence.
FDA review July 2026
Seven peptides, two days, one docket. What the meeting means and what it does not.